Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
MEDICAL-TREATMENT OF MIGRAINE - FROM MECHANISMS OF ACTION TO CONTRAINDICATIONS
Autore:
HIGELIN F; ANNONI JM;
Indirizzi:
5 RUE HENRI CHRISTINE CH-1205 GENEVA SWITZERLAND HOP CANTONAL UNIV GENEVA,DEPT MED COMMUNAUTAIRE GENEVA SWITZERLAND HOP CANTONAL UNIV GENEVA,NEUROL CLIN GENEVA SWITZERLAND
Titolo Testata:
Schweizerische medizinische Wochenschrift
fascicolo: 10, volume: 128, anno: 1998,
pagine: 374 - 383
SICI:
0036-7672(1998)128:10<374:MOM-FM>2.0.ZU;2-A
Fonte:
ISI
Lingua:
ENG
Soggetto:
DOUBLE-BLIND; SUBCUTANEOUS SUMATRIPTAN; ERGOTAMINE TARTRATE; NATIONWIDE SURVEY; ORAL SUMATRIPTAN; SODIUM VALPROATE; PROPHYLAXIS; PLACEBO; FLUNARIZINE; ATTACKS;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
73
Recensione:
Indirizzi per estratti:
Citazione:
F. Higelin e J.M. Annoni, "MEDICAL-TREATMENT OF MIGRAINE - FROM MECHANISMS OF ACTION TO CONTRAINDICATIONS", Schweizerische medizinische Wochenschrift, 128(10), 1998, pp. 374-383

Abstract

Management of migraine patients with or without aura must include appropriate medication to treat the attack and long-term preventive therapy, especially if the frequency of the attacks is greater than 2-4 permonth. In both cases the choice of treatment depends on its efficacy and side effects. With regard to acute drug therapy, group studies do not suggest that ergot derivatives and sumatriptan are superior to simple analgesics and anti-inflammatory drugs, particularly if a prokinetic agent is added. These new are indicated for severe attacks to more conventional therapy. Chronic drug abuse may induce drug-induced or rebound headaches. As regards long-term prophylaxis, group studies suggest that calcium antagonists and 5-HT-influencing drugs are superior concerning attacks frequency to beta-blocking agents, but involve very frequent side effects (weight gain and somnolence). Interesting preliminary results have also been reported with valproate and enalapril, which will need confirmation by controlled studies. Finally the choice ofdrug must take into account the patient's comorbidities (cardiovascular diseases, asthma, diabetes etc).

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/09/20 alle ore 01:53:21